SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/04/24 Iovance Biotherapeutics, Inc. 8-K:8,9 3/04/24 11:224K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 26K 2: EX-99.1 Miscellaneous Exhibit HTML 15K 6: R1 Cover HTML 47K 8: XML IDEA XML File -- Filing Summary XML 11K 11: XML XBRL Instance -- tm247846d1_8k_htm XML 16K 7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.LAB XBRL Labels -- iova-20240304_lab XML 96K 5: EX-101.PRE XBRL Presentations -- iova-20240304_pre XML 64K 3: EX-101.SCH XBRL Schema -- iova-20240304 XSD 12K 9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 10: ZIP XBRL Zipped Folder -- 0001104659-24-030249-xbrl Zip 20K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): i March 4, 2024
i IOVANCE BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
i Delaware | ||
(State of Incorporation) | ||
i 001-36860 | i 75-3254381 | |
Commission File Number | (I.R.S. Employer Identification No.) | |
i 825 Industrial Road, i Suite 400 | ||
i San Carlos, i CA | i 94070 | |
(Address of Principal Executive Offices) | (Zip Code) | |
( i 650) i 260-7120 | ||
(Registrant’s Telephone Number, Including Area Code) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company i ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered |
i Common stock, par value $0.000041666 per value | i IOVA | i The Nasdaq Stock Market, LLC |
Item 8.01. Other Events.
On March 4, 2024, Iovance Biotherapeutics, Inc. issued a press release announcing a clinical program update for the IOV-LUN-202 registrational trial investigating LN-145 TIL cell therapy in non-small cell lung cancer.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description | |
99.1 | Press Release dated March 4, 2024. | |
104 | Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Iovance Biotherapeutics, Inc. | ||
Dated: March 4, 2024 | By: | /s/ Frederick G. Vogt |
Name: | Frederick G. Vogt, Ph.D., J.D. | |
Title: | Interim CEO and General Counsel |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period end: | 3/4/24 | None on these Dates | ||
List all Filings |